OPA-6566: Phase I/II started

Acucela Inc. (Seattle, Wash.) began a single-blind, placebo-controlled, dose-escalation, U.S. Phase I/II trial in about 120 patients comparing OPA-6566 vs. daily latanoprost. Patients will receive OP...